Guardant Health AMEA wins Team of the Year and Executive of the Year at the SBR Management Excellence Awards 2020
Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence Awards 2020.
The precision oncology company is fully focused on guiding treatment decisions for advanced cancer patients in AMEA. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample receipt in the laboratory.
“These SBR Management Excellence Awards are testament to the diligence and consolidated efforts of my team members who are daily impacting the lives of advanced cancer patients in Asia, Middle East and Africa through the advocacy of the Guardant360 test. I would like to thank all the oncologists who have been ordering our test, the patients who have chosen Guardant360 as their preferred liquid biopsy and our channel partners for their unwavering support,” said Simranjit Singh, Chief Executive Officer of Guardant Health AMEA who was elated to receive both awards on behalf of the company. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s companion diagnostic, the Guardant360® CDx test, for comprehensive tumor mutation profiling across all solid cancers, making it the first comprehensive liquid biopsy to receive U.S. FDA approval.
During this unprecedented time of the COVID-19 pandemic, liquid biopsies are particularly advantageous as many hospitals are experiencing difficulties in scheduling tissue biopsies. Aside from minimising the vulnerable patient’s time spent in the hospital and decreasing the risk of viral infection, as part of the company’s mobile phlebotomy services for advanced cancer patients, phlebotomists visit the patients’ homes to obtain blood samples for testing. Guardant Health AMEA’s innovative strategies this year included organising 16 webinars to keep oncologists engaged as face-to-face meetings could not be conducted due to the pandemic. These online seminars served as platforms for peer-to-peer education sessions where top oncologists discussed their patient cases and shared the advantages of using the Guardant360 test in clinical practice.
The company’s effective patient-centric approach has been lauded by leading medical oncologists, including Prof. Byoung Chul Cho, a well-known lung cancer specialist from the Division of Medical Oncology at Yonsei Cancer Center in Seoul, South Korea, who said, “I strongly believe in fast action against growing tumour and Guardant360 has made this possible in my clinic.”
According to Dr. Shaheenah Dawood, Associate Professor of Clinical Oncology at Mediclinic City Hospital in Dubai, UAE, “In several cases of breast cancer where the disease progresses to the bone, liquid biopsies like Guardant360 become very useful in clinical practice as it’s very difficult to biopsy bone. In such cases, this test gives us the comprehensive genomic information required to treat patients appropriately.”
About Guardant Health AMEA
Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs.
In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been ordered by more than 7,000 oncologists and over 60 biopharmaceutical companies. Visit us online at www.guardanthealthamea.com.